This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Approaches to outsourcing clinical trials have changed significantly in recent years. Mixing of service models — a strategy that drugdevelopers are leveraging now more than ever — can bring life-changing therapies to market faster.
Unlocking new levels of value with expanded offerings We are launching more dynamic and integrated service offerings that leverage the very latest automation and integrations to accelerate your unique drugdevelopment journey in new and different ways.
Find out solutions to mitigate the impact from clinicalsupply chain risk and discover how to improve dynamic drugsupply forecasting strategies. Enrolling study subjects, setting up patient randomization and managing drugsupply are critical to the success of a clinical trial.
Despite their exciting potential, the smooth operation of cell therapy development trials requires extraordinary orchestration, perfectly aligning the product and patient journeys. While clinicalsupply is essential to any successful trial, autologous cell therapy trials occupy the far end of the spectrum regarding risk tolerance.
The current landscape of protein drugdevelopment is characterised by accelerated timelines where new drugs are approved in months rather than years. In recent years, the biopharmaceutical industry has identified rapid Toxicology (Tox) material supply as the new critical path to IND readiness.
Regulatory Excellence - Licenses for Schedule I through IV drug substances. Adherence to harmonized pharmacy-specific SOPs based on cGMP principles at our three clinical pharmacology units. Electronic security access to the pharmacy and video monitoring. - 24/7 monitoring of temperature and humidity.
Drugdevelopment is a long process, and patients are waiting. What has the impact of summer been on recruiting efforts and the ability to manage clinical trial participants? Or maybe you are nearing the clinic. Have you identified and reached out to the PIs and potential clinical trial sites? Don’t get me wrong.
Definition of the manufacturing process description The Parenteral Drug Association defines the MPD as: A tool used to assist in execution of risk assessments, in the development of the Control Strategy, and for transfer of the process for commercial manufacturing.
The collaboration aims to leverage Molecular Partners’ proprietary DARPin® technologies and Novartis’ broad expertise in global drugdevelopment, regulatory affairs, manufacturing and commercialization to rapidly advance the program in keeping with the unprecedented global urgency created by the pandemic.
The companies are exploring these advances through their newly created Pfizer Amazon Collaboration Team (PACT) initiative, which applies AWS capabilities in analytics, machine learning, compute, storage, security, and cloud data warehousing to Pfizer laboratory, clinical manufacturing and clinicalsupply chain efforts.
Transform Your CDMO Experience By Choosing The Right Partner Learn how the right CDMO partner can help biopharma companies navigate challenges and accelerate drugdevelopment. sdees Thu, 02/06/2025 - 11:32 Learn how the right CDMO partner can help biopharma companies navigate challenges and accelerate drugdevelopment.
However, achieving this requires drugdevelopers to navigate a highly complex and competitive environment. Delays in clinical trials can have significant financial consequences for sponsors. 1 provider of clinical research solutions , our teams deliver 1.5x The challenges are compounded by increasing trial complexities.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content